Oral repaglinide is a rapid-acting insulinotropic agent that reduces postprandial glucose by targeting early insulin release, and lowering postprandial glucose is considered to be an important factor in the reduction in long-term cardiovascular complications of diabetes. Here, INS is linked to diabetes mellitus.